drugset / Trial / NCT00686998
Phase IIA Study in Patients With Schizophrenia
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
Timeline
- Start
- 2008-05
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olanzapine | Small molecule | 15 mg | Oral |
| Subject | PAVINETANT | Small molecule | 40 mg | Oral |